Oxford BioMedica plc Director's Share Purchase

RNS Number : 8404N
Oxford Biomedica PLC
12 September 2013

For immediate release

12 September 2013


Oxford BioMedica plc Director's Share Purchase


Oxford, UK - 12 September 2013: Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), the leading gene-based biopharmaceutical company, was informed on 12 September 2013 that one of its Directors had acquired ordinary shares of 1p each ("Ordinary Shares") as follows:






Interest after purchase

Director / PDMR


Price per share (p)

Number of Ordinary Shares acquired on

12 September 2013

Number of Ordinary Shares

% of total

issued share capital

Timothy Watts







The issued share capital of the Company is 1,416,149,005 1p ordinary shares.




For further information, please contact:


Oxford BioMedica plc:

Lara Mott, Head of Investor Relations and Corporate Communications


Tel: +44 (0)1865 783 000


Nomura Code Securities Limited:

Juliet Thompson/Chris Golden


Tel: +44 (0)20 7776 1200


Media/Financial Enquiries:

Mary-Jane Elliott/Emma Thompson/Matthew Neal

Consilium Strategic Communications


Tel: +44 (0)20 7920 2354



Notes to editors


1. About Oxford BioMedica®

Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient LentiVector® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline with current partners and licensees including Sanofi, Pfizer, Novartis, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions, ImaginAb and Immune Design Corp. Further information is available at www.oxfordbiomedica.co.ukand www.oxbsolutions.co.uk.

This information is provided by RNS
The company news service from the London Stock Exchange